On June 30, 2023, Cumberland Pharmaceuticals Inc. presented results from an interim analysis for the FIGHT DMD trial at the 29th annual Parent Project Muscular Dystrophy Conference in Dallas, Texas. The interim analysis was conducted on data from 25 patients with Duchenne muscular dystrophy ("DMD") who completed six of the twelve total months of treatment and assessments. Both doses of ifetroban were reported well-tolerated in DMD participants ages 7 years of age or older.

There was also a positive trend in leg muscle strength, but no statistically significant differences were yet identified at this early time point. Cumberland is developing ifetroban a new chemical entity for series of indications that address unmet medical needs. Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist.

Ifetroban demonstrates high affinity for TPr on many cell types including platelets, vascular and airway smooth muscle, andibroblasts, and lacks agonistic activity. Ifetroban also displays anti-platelet, antivasospastic, antifibrotic, and antibronchospastic activities and is effective in certain preclinical models of vasospasm, thrombosis, reperfusion injury, cardiac fibrosis, lung fibrosis and endothelial dysfunction, including models that are insensitive to aspirin. Cumberland is sponsoring the FIGHT DMD trial, a multicenter, randomized, placebo-controlled Phase II study evaluating the safety, pharmacokinetics and efficacy of two doses of oral ifetroban for the treatment of the cardiomyopathy associated DMD, a rare and fatal genetic disorder.

This trial is evaluating 12 months of oral ifetroban in 24 subjects with early-stage cardiomyopathy and 24 subjects with advance stage heart disease across 10 U.S. centers that specialize in DMD cardiomyopathy. The safety and efficacy endpoints include left ventricular ejection fraction using cardiac MRI, pulmonary function, quantitative muscle strength, daily activity, and quality of life measures. The U.S. Food and Drug Administration Orphan Product Division awarded Cumberland $1 million in funding under its orphan products grants program to support this trial.

This was the first DMD trial awarded such funding. The Company plans to complete each of its ifetroban sponsored studies, analyze data, announce top-line results, and then decide on the best development path for the registration of ifetroban, which has the potential to benefit many patients with orphan diseases that represent unmet medical needs.